DN as an important cause of CKD, and some drugs treated with diabetes like SGLT2 inhibitors have shown renal protective effects (Sharma et al., 2017; Kelly et al., 2019), as a typical drug of SGLT2 inhibitors, dapagliflozin’s renal protective effects on CKD have been demonstrated in patients with and without diabetes (Kurata and Nangaku, 2022), and it has also displayed antirenal fibrosis activities in animal models induced by unilateral ureter obstruction and alcohol damage (Wu et al., 2021; Xuan et al., 2021; Liu et al., 2022). Here, SLC5A2 is linked to chronic kidney disease.